KR20230127292A - 항-cd73 항체의 제제 - Google Patents

항-cd73 항체의 제제 Download PDF

Info

Publication number
KR20230127292A
KR20230127292A KR1020237025806A KR20237025806A KR20230127292A KR 20230127292 A KR20230127292 A KR 20230127292A KR 1020237025806 A KR1020237025806 A KR 1020237025806A KR 20237025806 A KR20237025806 A KR 20237025806A KR 20230127292 A KR20230127292 A KR 20230127292A
Authority
KR
South Korea
Prior art keywords
ser
cancer
composition
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237025806A
Other languages
English (en)
Korean (ko)
Inventor
징 주
쩌루 장
샹핑 주
야리 위
Original Assignee
아이-맵 바이오파마 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이-맵 바이오파마 컴파니 리미티드 filed Critical 아이-맵 바이오파마 컴파니 리미티드
Publication of KR20230127292A publication Critical patent/KR20230127292A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020237025806A 2020-12-30 2021-05-08 항-cd73 항체의 제제 Pending KR20230127292A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020141601 2020-12-30
CNPCT/CN2020/141601 2020-12-30
PCT/CN2021/092485 WO2022142053A1 (en) 2020-12-30 2021-05-08 Formulations of anti-cd73 antibodies

Publications (1)

Publication Number Publication Date
KR20230127292A true KR20230127292A (ko) 2023-08-31

Family

ID=82258959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237025806A Pending KR20230127292A (ko) 2020-12-30 2021-05-08 항-cd73 항체의 제제

Country Status (8)

Country Link
US (1) US20240101698A1 (cg-RX-API-DMAC7.html)
EP (1) EP4271410A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505128A (cg-RX-API-DMAC7.html)
KR (1) KR20230127292A (cg-RX-API-DMAC7.html)
CN (1) CN116615458A (cg-RX-API-DMAC7.html)
AU (1) AU2021415180A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203441A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022142053A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025021098A1 (zh) * 2023-07-24 2025-01-30 石药集团巨石生物制药有限公司 重组人源化抗cd73单克隆抗体的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578131A1 (en) * 2004-09-10 2006-03-23 Wyeth Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
WO2010056804A1 (en) * 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
CN102512384B (zh) * 2011-12-29 2014-11-26 嘉和生物药业有限公司 一种冻干剂型蛋白组合物及其制备方法
CN108025072A (zh) * 2015-09-22 2018-05-11 辉瑞公司 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン,エルエルシー 抗pd−l1および抗ctla−4抗体の共製剤を含む組成物
CA3045376C (en) * 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US20210054079A1 (en) * 2018-04-25 2021-02-25 Medimmune Limited Formulations of human anti-pd-li antibodies
CN112041348B (zh) * 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
SG11202105152YA (en) * 2018-11-30 2021-06-29 Abl Bio Inc Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物

Also Published As

Publication number Publication date
CN116615458A (zh) 2023-08-18
EP4271410A1 (en) 2023-11-08
WO2022142053A1 (en) 2022-07-07
AU2021415180A1 (en) 2023-07-06
CA3203441A1 (en) 2022-07-07
EP4271410A4 (en) 2025-08-13
US20240101698A1 (en) 2024-03-28
JP2024505128A (ja) 2024-02-05

Similar Documents

Publication Publication Date Title
JP7653465B2 (ja) 単独およびプログラム死受容体1(pd-1)抗体と組み合わされた抗ctla4抗体の安定な製剤、ならびにその使用方法
US20230321234A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR102770786B1 (ko) 항-tigit 항체 단독의, 및 프로그램화된 사멸 수용체 1 (pd-1) 항체와 조합된 항-tigit 항체의 안정한 제제 및 그의 사용 방법
TWI880888B (zh) 抗體-藥物結合物之製劑及其冷凍乾燥方法
US20220387314A1 (en) Albumin-pd-1 paclitaxel nanoparticle complex compositions and methods of making and using the same
US20080166346A1 (en) Lyophilised Preparation Comprising Antibodies Against The EFG Receptor
KR20210089215A (ko) 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CN110913906A (zh) 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
EP3991745A1 (en) Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof
JP7805289B2 (ja) 抗コネキシン抗体製剤
WO2022128716A1 (en) Pharmaceutical composition comprising a bispecific anti-muc1/egfr antibody-drug conjugate
CA3252354A1 (en) Pharmaceutical composition containing an anti-nectin-4 antibody conjugate and its use
KR100700963B1 (ko) 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제
TW202511293A (zh) 包含抗ccr8抗體的製劑及其用途
KR20260011720A (ko) 항체-약물 접합체를 포함하는 약제 조성물
KR20240024941A (ko) 항-pd1 항체의 제제
WO2022142053A1 (en) Formulations of anti-cd73 antibodies
US20240382411A1 (en) Composition comprising pd-l1 antigen-binding fragment and use thereof
EA052347B1 (ru) Композиция, содержащая фрагмент, связывающий антиген pd-l1, и ее применение
RU2789476C2 (ru) Получение конъюгата антитело-лекарственное средство и его лиофилизация
HK40103088A (en) Anti-il5r antibody formulations
RU2820576C2 (ru) Стабильные составы антител против tigit, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
HK40077586A (en) Anto-connexin antibody formulations
KR20240108799A (ko) 항 엽산 수용체 접합체 암 요법
KR20230053012A (ko) 항-pd-1 항체를 포함하는 암의 치료용 약학적 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902